Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Lillys ESMO oncology updates, especially early ovarian-cancer data for Sofe-M with bevacizumab, are drawing attention as investors weigh the pipelines potential to diversify beyond obesity drugs. Traders are also discussing olomorasib lung-cancer findings, while the stocks pullback has prompted mixed reactions about whether the positive pipeline news can support further gains.

Caterpillars upcoming quarterly report is the main focus as shares pull back sharply, with traders debating whether strong backlog and data-center power demand can withstand already-high expectations. Some expect further downside if guidance or orders disappoint, while others view the oversold pullback as a buying opportunity.

Phase 2 results for pumitamig plus docetaxel in advanced lung cancer are drawing attention, with traders weighing the reported response rate and progression-free survival against questions about how durable the benefit will be. The reaction is tempered by broader concerns about BioNTechs earlier clinical setbacks and leadership transition.

Positive prostate-cancer trial results are drawing attention, including reports of lower recurrence risk with ERLEADA and a tumor-response signal for an early-stage treatment. Traders see the data as supportive but debate whether it can move the shares meaningfully or is already priced in.

FICO is drawing attention over mortgage-market changes that put VantageScore on the same pricing grid as FICO and threaten the companys scoring monopoly and pricing power; traders also point to Rocket Mortgages planned VantageScore use and its lower cost. The debate is whether lenders will meaningfully switch or FICOs established position and direct-licensing option will limit the impact, fueling sharp bearish views alongside dip-buying and rebound speculation.

GLXY is drawing attention ahead of its earnings report as traders debate whether results can halt a sharp selloff tied to weakness in crypto and AI/data-center stocks. Bearish posts fear disappointing results and exposure to CoreWeave, while some investors see the decline as overdone and are positioning for a rebound.

AXSMs steep selloff has centered on uncertainty over Auvelitys launch for Alzheimers agitation, as prescription data has not shown the acceleration some investors expected; the Nov. 2 Q3 report is widely viewed as a key test of uptake and commercial execution. Some traders fear weak adoption and rising expenses, while others argue that samples and long-term-care prescriptions may be undercounted and remain bullish on the launchs longer-term potential.

Crypto-market volatility and Coinbases upcoming quarterly report are driving attention, with traders focused on the stocks sharp swings and repeated underperformance versus Bitcoineven during crypto rebounds. Sentiment is largely frustrated and bearish over the weak price action and declining revenue trend, though some expect earnings or a crypto recovery to support a bounce.

KTOS is drawing attention after a prolonged selloff toward 52-week lows, with traders debating analyst downgrades, insider selling, valuation and whether the company can turn its defense-contract pipeline into stronger profits and cash flow. Some see the pullback as overdone given reported contract wins and drone, hypersonics and space demand, while others are cautious ahead of the Q3 report.

Reports of Toshiba expanding HDD capacity for AI data centers, followed by reports that Seagate and Toshiba are bidding for TDKs HDD-head business, have fueled sharp volatility in STX and other storage shares. Traders debate whether added competition threatens the industrys supply-constrained pricing power or whether strong AI-related demand and Seagates vertical integration make the selloff overdone.